Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0596263 (
carcinogenesis
)
64,820
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The patient was a 73-year-old man with ascending colon cancer and synchronous liver metastases. A right hemicolectomy with a lymph node dissection was performed for the primary lesion. The resected specimen revealed a KRAS codon 12 mutation. After 6 courses of chemotherapy with capecitabine, oxaliplatin, and bevacizumab(Bv), we performed a partial hepatectomy and resection of the peritoneal dissemination. A computed tomography(CT)scan 5 months later revealed the recurrence of the liver metastases. After 8 courses of chemotherapy with 5-fluorouracil, Leucovorin, irinotecan, and Bv, we performed a partial hepatectomy. CT scan after 13 months revealed a recurrence in the peritoneal dissemination in the Douglas pouch and the right subphrenic space; therefore, we performed a low anterior resection and resection of the peritoneal dissemination with curative intent. CT scan after 19 months revealed a recurrence in the right subphrenic dissemination, a lung metastasis, and pleural dissemination. Chemotherapy with 5-fluorouracil, Leucovorin, and Bv was administered for 2 years and 5 months. After 5 years and 9 months of the primary operation, the patient is alive. Recently, we have focused on the mechanism of multidrug resistance through NAD(P)H:
quinone oxidoreductase
-1(NQO1)overexpression, which can be used to determine the role of an enzyme in sensitivity to toxicity and
carcinogenesis
. In this case, the pathological examination of the resected specimen revealed NQO1 negative expression. In conclusion, NQO1 may play a significant role in chemotherapy resistance in colorectal cancer patients.
...
PMID:[A Case of Ascending Colon Cancer with Synchronous Liver Metastases and Peritoneal Dissemination]. 2939 55
Women are increasingly using botanical dietary supplements (BDS) to reduce menopausal hot flashes. Although licorice (
Glycyrrhiza
sp.) is one of the frequently used ingredients in BDS, the exact plant species is often not identified. We previously showed that in breast epithelial cells (MCF-10A),
Glycyrrhiza glabra
(GG) and
G. inflata
(GI), and their compounds differentially modulated P450 1A1 and P450 1B1 gene expression, which are responsible for estrogen detoxification and genotoxicity, respectively. GG and isoliquiritigenin (LigC) increased
CYP1A1
, whereas GI and its marker compound, licochalcone A (LicA), decreased
CYP1A1
and
CYP1B1
The objective of this study was to determine the distribution of the bioactive licorice compounds, the metabolism of LicA, and whether GG, GI, and/or pure LicA modulate NAD(P)H
quinone oxidoreductase
(NQO1) in an ACI rat model. In addition, the effect of licorice extracts and compounds on biomarkers of estrogen chemoprevention (
CYP1A1
) as well as
carcinogenesis
(
CYP1B1
) was studied. LicA was extensively glucuronidated and formed GSH adducts; however, free LicA as well as LigC were bioavailable in target tissues after oral intake of licorice extracts. GG, GI, and LicA caused induction of NQO1 activity in the liver. In mammary tissue, GI increased
CYP1A1
and decreased
CYP1B1
, whereas GG only increased
CYP1A1
LigC may have contributed to the upregulation of
CYP1A1
after GG and GI administration. In contrast, LicA was responsible for GI-mediated downregulation of
CYP1B1
These studies highlight the polypharmacologic nature of botanicals and the importance of standardization of licorice BDS to specific
Glycyrrhiza
species and to multiple constituents.
...
PMID:Evidence for Chemopreventive and Resilience Activity of Licorice:
Glycyrrhiza Glabra
and G.
Inflata
Extracts Modulate Estrogen Metabolism in ACI Rats. 3028 22
<< Previous
1
2
3
4
5